Please assess the completion status of the following clinical trial:

Trial Title: SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed inform consent form.~2. Age \>= 18 years and \<= 70 years.~3. Histologically or cytologically confirmed small cell lung cancer.~4. ED-SCLC according to Veterans Administration Lung Study Group.~5. Radiographically progression following a platinum-based standard prior chemotherapy regimen.~6. Eastern Cooperative Oncology Group performance status of 0 or 1.~7. Measurable disease as defined by RECIST v1.1.~8. Life expectancy \>= 8 weeks.~9. Adequate hematologic and end organ function.~Exclusion Criteria:~1. Histologically or cytologically confirmed mixed non-small cell and small cell carcinoma.~2. Prior exposure to therapeutic anticancer vaccines; prior exposure to any T cell co-stimulatory therapy or immune checkpoint inhibitors, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies.~3. Prior exposure to anti-VEGF or anti-VEGFR therapy.~4. Active brain metastasis or meningeal metastasis.~5. Clinically significant third space effusion (e.g., uncontrolled pericardial effusion, ascites or pleural effusion by extraction or other treatment).~6. Known hypersensitivity to study drug or any of its excipients; known hypersensitivity to any antibody.~7. Treatment with any other investigational agent or participation in another clinical trial within 4 weeks prior to screening.~8. Other conditions that the investigator thinks unsuitable in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
- B (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (5 Days on, 2 Days off)
- C (SHR-1210+Apatinib) (Type: EXPERIMENTAL): SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD (7 Days on, 7 Days off)

Based on this trial design, predict the completion outcome and termination type (if applicable).